Aurora’s international network, GlobalHealth PR launches the Global Guide to Market Access to help navigate the complexities of this area

The Guide provides readers key insights into the biopharmaceutical reimbursement environment across 26 countries

Market Access in the UK can be complex and varies depending on which of the four devolved nations products are looking to be made accessible in. While the pricing strategies (the Voluntary and Statutory Schemes) are consistent across England, Scotland, Wales, and Northern Ireland, the reimbursement routes vary country to country.

The UK’s health institutions — the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) in particular – are key influencers, not only in the UK countries, but across Europe and the rest of the world. England’s payer decision makers seek to reward innovation while ensuring “value for money spent.” This occurs through several appraisal processes, which are used depending on the type of medicine. Market Access, therefore, can be a difficult area to navigate for clients not only in the UK, but across the world.

It is with this in mind that the GlobalHealth PR (GHPR) team – the largest independent health and science communications agency partnership worldwide – has developed the Global Guide to Market Access (GGMA). Aurora is proud to present the guide developed collaboratively with our global partners.

The GGMA provides readers a window into the biopharmaceutical reimbursement environment across 26 countries and is the result of a global study carried out by GHPR. 

Using easy-to-understand language, these guides break down the complex pathways that a medicine must take in order to achieve patient access and be reimbursed.

Each country guide is divided into three sections:

  • Payer Stakeholders
  • Important Points to Keep in Mind
  • Implications for Industry

The resource provides a window into the GHPR network, providing expert Market Access perspectives at a local level, across the globe. For contacts who might be new in their positions at pharmaceutical companies, this guide allows them to quickly get up-to-speed on the Market Access landscape in their country (or indeed others).

The GGMA not only details valuable information on the route to reimbursement in each country, but also shares useful insights on how best to approach each option; what factors may help you in obtaining a favourable recommendation, weighing up the advantages and disadvantages of each option, giving you all the information, you need in deciding the best route to market.

To find out more about GlobalHealth PR, to receive a copy of the GGMA, and to learn about how the Aurora and GHPR teams can help you with your market access needs, please contact the UK team at:

Related Blog posts

Patient involvement and engagement

“Hard to reach” is no longer an acceptable excuse

Our duty as communicators in addressing health inequality and the social determinants of health Perhaps one of the few silver linings of COVID-19 is the unprecedented scientific collaboration in tackling…

Corporate counsel and implementation

‘What can’t we afford to treat anymore?’

“The pharma industry in this country… could be an engine to modernise, improve and grow the economy, and we’ll all benefit from that” – Sir David Nicholson On Monday evening,…

Post a comment

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Get in touch

The quickest way to get in contact with us is to give a us call or ping us an email.

Sign up to our newsletter

Keep up to date with the great things we’re doing